EMA/472965/2018

European Medicines Agency decision

P/0234/2018

of 15 August 2018

on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix), (EMEA-000455-PIP02-10-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0234/2018

of 15 August 2018

on the acceptance of a modification of an agreed paediatric investigation plan for vortioxetine (Brintellix), (EMEA-000455-PIP02-10-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/130/2011 issued on 8 June 2011, the decision P/0282/2011 issued on 29 November 2011, the decision P/0239/2014 issued on 22 September 2014 and the decision P/0190/2015 issued on 4 September 2015,

Having regard to the application submitted by H. Lundbeck A/S on 6 April 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 June 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for vortioxetine (Brintellix), film-coated tablet, age appropriate oral liquid dosage form, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to H. Lundbeck A/S, Ottiliavej 9, 2500 – Valby, Denmark.

EMA/PDCO/231481/2018
London, 29 June 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000455-PIP02-10-M04

Scope of the application

Active substance(s):

Vortioxetine

Invented name:

Brintellix

Condition(s):

Treatment of major depressive disorder

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Age appropriate oral liquid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

H. Lundbeck A/S

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, H. Lundbeck A/S submitted to the European Medicines Agency on 6 April 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/130/2011 issued on 8 June 2011, the decision P/0282/2011 issued on 29 November 2011, the decision P/0239/2014 issued on 22 September 2014 and the decision P/0190/2015 issued on 4 September 2015.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 2 May 2018.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition:

Treatment of major depressive disorder

The waiver applies to:

- all subsets of the paediatric population from birth to less than 24 months of age;
- film-coated tablet, age appropriate oral liquid dosage form, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

The waiver applies to:

- all subsets of the paediatric population from 24 months to less than 7 years of age;
- film-coated tablet, age appropriate oral liquid dosage form, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible in the specified paediatric subset.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of major depressive disorder

2.1.1. Indication(s) targeted by the PIP

Treatment of major depressive disorder

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 7 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age appropriate oral liquid dosage form

2.1.4. Studies

Area	Number of studies	Description
Quality	1	**Study 1:** Development of age-appropriate liquid formulation for oral use.

Area	Number of studies	Description
Non-clinical	3	**Study 2:** Toxicokinetic study in juvenile animals. **Study 3:** Dose-range finding study in juvenile animals. **Study 4:** Toxicity study in juvenile animals.
Clinical	6	**Study 5:** Open-label study to assess the pharmacokinetics and tolerability of multiple oral dosing of vortioxetine in children and adolescent patients with a DSM-IV diagnosis of depressive or anxiety disorder (12708A). **Study 6:** Two-phase, single- and double-blind, randomised, placebo-controlled, multicentre, short-term study of vortioxetine and fluoxetine in paediatric patients with major depressive disorder (MDD) from 7 to less than 12 years of age (12709A). **Study 7:** Two-phase, single- and double-blind, randomised, placebo-controlled and active comparator, 4 arm, multicentre, short-term study of vortioxetine and fluoxetine in paediatric patients with major depressive disorder (MDD) from 12 to less than 18 years of age (12710A). **Study 8:** Double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study of vortioxetine in paediatric patients with major depressive disorder (MDD) from 7 to less than 18 years of age (13546A). **Study 9:** Long-term, open-label, flexible-dose, extension study of vortioxetine in paediatric patients with major depressive disorder (MDD) from 7 to less than 18 years of age (12712A). **Study 10:** Long-term, open-label, flexible-dose, extension study of vortioxetine in paediatric patients with major depressive disorder (MDD) from 7 to less than 18 years of age who have completed Study 12712A (12712B).

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes

Date of completion of the paediatric investigation plan:	By June 2024
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

- Treatment of major depressive disorder

Authorised indication(s):

Brintellix is indicated for the treatment of major depressive episodes in adults.

Authorised pharmaceutical form(s):

Film-coated tablet

Oral drops, solution

Authorised route(s) of administration:

Oral use